Application and Advances of Non-in vasive Magnetic Resonance Proton Density Fat Fraction in Hepatic Steatosis

Boli Ruan; Yao Zhang; Hongwei Lei

doi:10.54097/wr4x8210

Authors

Boli Ruan
Yao Zhang
Hongwei Lei

DOI:

https://doi.org/10.54097/wr4x8210

Keywords:

Magnetic Resonance Imaging (MRI), Proton Density Fat Fraction (PDFF), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Nonalcoholic Fatty Liver Disease (NAFLD), Hepatic Steatosis, Non-invasive Diagnosis, Quantitative Imaging

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 32% of the global adult population, represents a leading cause of chronic liver disease. Hepatic steatosis, characterized by abnormal lipid accumulation in hepatocytes, serves as a fundamental histological hallmark and a key driver of disease progression towards metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Accurate, non-invasive quantification of liver fat content is therefore paramount for diagnosis, risk stratification, and therapeutic monitoring in MASLD. Magnetic Resonance Imaging-proton density fat fraction (MRI-PDFF), based on chemical shift-encoded water-fat separation, has emerged as a highly accurate, reproducible, and quantitative non-invasive biomarker for assessing hepatic steatosis. This review synthesizes current evidence demonstrating the superior diagnostic performance of MRI-PDFF in grading hepatic steatosis compared to traditional techniques like Controlled Attenuation Parameter (CAP) and transient elastography (TE), as evidenced by high area-under-the-receiver-operating-characteristic-curve (AUROC) values across multiple studies. Furthermore, MRI-PDFF plays a pivotal role in evaluating treatment efficacy in clinical trials, effectively detecting significant reductions in liver fat content in response to pharmacotherapy. While MRI-PDFF excels in fat quantification, its combination with other MRI-based techniques (e.g., Magnetic Resonance Elastography - MRE, corrected T1 - cT1) significantly enhances the non-invasive assessment of co-existing pathologies like MASH and fibrosis. Despite advantages such as whole-liver coverage and excellent reproducibility, limitations including high cost, technical standardization challenges, and restricted applicability in certain patient populations remain. In conclusion, MRI-PDFF stands as a cornerstone non-invasive tool for quantifying liver fat in MASLD, driving advancements in diagnosis, therapeutic monitoring, and clinical trial endpoints, with ongoing developments in multimodal approaches and standardization promising further optimization of MASLD management.

Downloads

Download data is not yet available.

References

[1] TENG M L, NG C H, HUANG D Q, et al. Global incidence and prevalence of nonalcoholic fatty liver disease [J]. Clin Mol Hepatol, 2023, 29(Suppl): S32-s42.

[2] HUANG D Q, EL-SERAG H B, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.

[3] LI J, ZOU B, YEO Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.

[4] DONGIOVANNI P, STENDER S, PIETRELLI A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver [J]. J Intern Med, 2018, 283(4): 356-370.

[5] AJMERA V, PARK C C, CAUSSY C, et al. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology, 2018, 155(2): 307-10.e2.

[6] CHALASANI N, YOUNOSSI Z, LAVINE J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J]. Hepatology, 2018, 67(1): 328-357.

[7] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1): 73-84.

[8] TAMAKI N, AJMERA V, LOOMBA R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD [J]. Nat Rev Endocrinol, 2022, 18(1): 55-66.

[9] CAUSSY C, REEDER S B, SIRLIN C B, et al. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials [J]. Hepatology, 2018, 68(2): 763-772.

[10] NEGRETE L M, MIDDLETON M S, CLARK L, et al. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects [J]. J Magn Reson Imaging, 2014, 39(5): 1265-1271.

[11] KANG G H, CRUITE I, SHIEHMORTEZA M, et al. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms [J]. J Magn Reson Imaging, 2011, 34(4): 928-934.

[12] PARK C C, NGUYEN P, HERNANDEZ C, et al. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease [J]. Gastroenterology, 2017, 152(3): 598-607.e2.

[13] GU J, LIU S, DU S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis [J]. Eur Radiol, 2019, 29(7): 3564-3573.

[14] STINE J G, MUNAGANURU N, BARNARD A, et al. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis [J]. Clin Gastroenterol Hepatol, 2021, 19(11): 2274-83.e5.

[15] GARTEISER P, CASTERA L, COUPAYE M, et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates [J]. JHEP Rep, 2021, 3(6): 100381.

[16] KIM G-A, CHO H C, JEONG S W, et al. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease [J]. Pharmaceuticals, 2023, 16(4): 623.

[17] CHO Y, RHEE H, KIM Y E, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study) [J]. BMC Med, 2022, 20(1): 93.

[18] ALKHOURI N, HERRING R, KABLER H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial [J]. J Hepatol, 2022, 77(3): 607-618.

[19] TROELSTRA M A, WITJES J J, VAN DIJK A M, et al. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort [J]. J Magn Reson Imaging, 2021, 54(6): 1937-1949.

[20] ALSAQAL S, HOCKINGS P, AHLSTRöM H, et al. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis [J]. J Magn Reson Imaging, 2022, 56(2): 368-379.

[21] ALLEN A M, SHAH V H, THERNEAU T M, et al. The Role of Three‐Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery [J]. Hepatology, 2020, 71(2): 510-521.

[22] IMAJO K, TETLOW L, DENNIS A, et al. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort [J]. World J Gastroenterol, 2021, 27(7): 609-623.

[23] KIM J W, LEE C H, YANG Z, et al. The spectrum of magnetic resonance imaging proton density fat fraction (MRI-PDFF), magnetic resonance spectroscopy (MRS), and two different histopathologic methods (artificial intelligence vs. pathologist) in quantifying hepatic steatosis [J]. Quantitative Imaging in Medicine and Surgery, 2022, 12(11): 5251-5262.